Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

McGill University

$30,000.00

Prostaglandin E2 EP receptor trafficking and nociception

EF 2013-14

Résumé
Numerous drugs or compounds induce biological functions inside the cells by binding to their own receptors at the cell surface and triggering subsequent intracellular signalling events. In response to the environmental changes, altering the receptor density at the cell surface through its trafficking is a key mechanism to modulate receptor induced cell functions. Prostaglandin E2 (PGE2) is a well known pain mediator abundantly produced in inflamed tissues. PGE2 causes pain through its EP receptors present in pain inducing nerve cells (nociceptors) by directly exciting nociceptors and by stimulating the release of pain causing peptides from these cells. Four EP receptors are located in discrete subcellular domains of nociceptors, with EP1 and EP2 localizing at the cell surface as well as in the intracellular pool while EP3 and EP4 being mainly intracellular. The discrete subcellular distribution of EP receptors is modifiable by pain states, suggesting that PGE2 is able to induce its receptor trafficking to and from the cell surface, thus binding more or fewer PGE2 and consequently enhancing or suppressing pain response. Indeed we also observed that that PGE2 increases the cell surface expression of EP4 receptors in cultured pain inducing nerve cells, which is normally stored in an intracellular pool. Based on these data, we hence hypothesize that PGE2 induces EP4 receptor trafficking to the cell surface of nociceptors to enhance pain response. A research program has been formulated to test this hypothesis. At the initial stage of this research program, we will aim at EP4 trafficking to and from the cell surface at rest and stimulated states, and its role in PGE2 induced pain peptide release. The significance of this research program is to narrow the knowledge gap in our understanding of EP receptor trafficking and its role in modulating PGE2 induced pain. Understanding the mechanisms governing EP receptor trafficking in nociceptors and its role in PGE2 induced pain will potentially open a novel therapeutic avenue to treat various pain conditions in which PGE2/EP receptor signalling is involved.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
356021-2011
Name nom
Ma, Weiya
Department département
Psychiatry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2011
Award amount
30000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Partie
3
Nb partie
5
Application title
Prostaglandin E2 EP receptor trafficking and nociception
Keyword
NSERC
Application summary
Numerous drugs or compounds induce biological functions inside the cells by binding to their own receptors at the cell surface and triggering subsequent intracellular signalling events. In response to the environmental changes, altering the receptor density at the cell surface through its trafficking is a key mechanism to modulate receptor induced cell functions. Prostaglandin E2 (PGE2) is a well known pain mediator abundantly produced in inflamed tissues. PGE2 causes pain through its EP receptors present in pain inducing nerve cells (nociceptors) by directly exciting nociceptors and by stimulating the release of pain causing peptides from these cells. Four EP receptors are located in discrete subcellular domains of nociceptors, with EP1 and EP2 localizing at the cell surface as well as in the intracellular pool while EP3 and EP4 being mainly intracellular. The discrete subcellular distribution of EP receptors is modifiable by pain states, suggesting that PGE2 is able to induce its receptor trafficking to and from the cell surface, thus binding more or fewer PGE2 and consequently enhancing or suppressing pain response. Indeed we also observed that that PGE2 increases the cell surface expression of EP4 receptors in cultured pain inducing nerve cells, which is normally stored in an intracellular pool. Based on these data, we hence hypothesize that PGE2 induces EP4 receptor trafficking to the cell surface of nociceptors to enhance pain response. A research program has been formulated to test this hypothesis. At the initial stage of this research program, we will aim at EP4 trafficking to and from the cell surface at rest and stimulated states, and its role in PGE2 induced pain peptide release. The significance of this research program is to narrow the knowledge gap in our understanding of EP receptor trafficking and its role in modulating PGE2 induced pain. Understanding the mechanisms governing EP receptor trafficking in nociceptors and its role in PGE2 induced pain will potentially open a novel therapeutic avenue to treat various pain conditions in which PGE2/EP receptor signalling is involved.